:omidubicel?

Arpita P Gandhi1, Laura F Newell1, Richard T Maziarz2

  • 1Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.

PubMed
概括

带血液移植 (CBT) 提供了一个替代的供体来源,但面临着挑战. 扩大带血产品Omidubicel在改善移植和降低移植患者感染风险方面表现有前途.